A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
Condition: Schizophrenia Interventions: Drug: Olanzapine; Drug: Paliperidone Sponsors: Beijing HuiLongGuan Hospital; WenZhou-Kangning Hospital Recruiting - verified September 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 20, 2016 Category: Research Source Type: clinical trials
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Condition: SchizophreniaIntervention: Drug: Paliperidone palmitate 3 month formulation (PP3M)Sponsor: Janssen-Cilag Ltd.Recruiting - verified May 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 14, 2016 Category: Research Source Type: clinical trials
